Funding for this research was provided by:
Joan and Irwin Jacobs Fund (N/A)
National Cancer Institute (P30 CA023100)
Received: 12 February 2020
Accepted: 10 June 2020
First Online: 9 July 2020
Ethics approval and consent to participate
: Not applicable.Data used in this study originate from the Angiosarcoma Project and The Cancer Genome Atlas program.The Angiosarcoma Project is a patient-driven initiative including genomic data, patient-reported data, medical record data, and pathology report data from 48 consented angiosarcoma patients. All annotations have been de-identified. More information is available at ExternalRef removed.The Cancer Genome Atlas project is a cancer genomics program led by the National Cancer Institute and the National Human Genome Research Institute, allowing the molecular characterization (genomic, epigenomic, transcriptomic, and proteomic data) of more than 20,000 primary cancer and matched normal samples spanning 33 cancer types. The corresponding data was collected respectively to the TCGA Human Subjects Protection and Data Access Policies available at ExternalRef removed.
: Not applicable (study using de-identified data).
: R.K. has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); Consulting or Advisory Role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, Pfizer, and Merck); Speaker’s fee (Roche); Research Funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq [All institutional]); Board Member (CureMatch, Inc., and CureMetrix, Inc.). M.W. has clinical research funding from Athenex and Adaptimmune and consultant fees from Adaptimmune, Tempus, and Deciphera.A.B. declares no competing interests.